Cobimetinib regulatory update

FDA accepted and granted Priority Review to an NDA from Roche’s Genentech unit for cobimetinib plus Zelboraf vemurafenib to treat BRAF V600 mutation-positive advanced melanoma. The PDUFA date is Aug...